Nicorandil reverses the behavioral changes and brain oxidative stress in a model of schizophrenia induced by ketamine in mice

被引:0
作者
Abdel-Salam O.M.E. [1 ]
El-Shamarka M.E.-S. [1 ]
机构
[1] Department of Toxicology and Narcotics, National Research Centre, Tahrir Street, Dokki, Cairo
关键词
Brain oxidative stress; Glibenclamide; Mice; Nicorandil; Open field; Social interaction;
D O I
10.1007/s00580-017-2471-x
中图分类号
学科分类号
摘要
We examined the effect of the KATP channel opener nicorandil and the KATP channel blocker glibenclamide on the behavioral and biochemical responses to ketamine in mice. Ketamine was injected at 30 mg/kg intraperitoneally (i.p.) daily for 2 weeks, and mice were then treated with either saline, glibenclamide (5 mg/kg), nicorandil (1 or 5 mg/kg), sucrose 1 g/kg, or glibenclamide + sucrose 1 g/kg, i.p. daily for another 8 days. The control group received only saline. Data indicated that (i) ketamine increased locomotion, rearing, and grooming behaviors. Locomotor activity increased in the center while rearing activity increased in the periphery and center of the open field. Social interaction was markedly decreased by ketamine. Nicorandil at 1 mg/kg increased and at 5 mg/kg produced marked depression in ambulation in the center of the field and in rearing in the field periphery. Locomotor activity and rearing of ketamine-treated mice were not affected by glibenclamide. Meanwhile, either agent reversed the increase in grooming and the inhibition of social interaction caused by ketamine. Sucrose had no significant effect on grooming or social interaction of mice given ketamine but increased ambulation and rearing activity in the field center. (ii) Ketamine caused a significantly elevated brain lipid peroxidation (malondialdehyde) while decreasing reduced glutathione, nitric oxide, and paraoxonase-1 activity. These biochemical alterations were markedly alleviated by nicorandil or glibenclamide. The study suggests a potential therapeutic value for the KATP channel opener nicorandil in the ketamine model of schizophrenia. © 2017, Springer-Verlag London.
引用
收藏
页码:955 / 963
页数:8
相关论文
共 66 条
  • [1] Abdel-Salam O.M.E., Youness E.R., Mohammed N.A., Omara E.A., Sleem A.A., Effect of ketamine on oxidative stress following lipopolysaccharide administration, Comp Clin Pathol, 24, pp. 53-63, (2015)
  • [2] Abdel-Salam O.M.E., Youness E.R., Mohammed N.A., Abu Elhamed W.A., Nuclear factor-kappa B and other oxidative stress biomarkers in serum of autistic children, Open J Mol Integr Physiol, 5, pp. 18-27, (2015)
  • [3] Ahern T.L., Herring A.A., Anderson E.S., Madia V.A., Fahimi J., Frazee B.W., The first 500: initial experience with widespread use of low-dose ketamine for acute pain management in the ED, Am J Emerg Med, 33, 2, pp. 197-201, (2015)
  • [4] Arruda M.O.V., Soares P.M., Honorio J.E.R., Lima R.C.S., Chaves E.M.C., Lobato R.F.G., Martin A.L.A.R., Sales G.T.M., Carvalho K.M., Assreuy A.M.S., de Brito E.M., Vasconcelos S.M.M., Activities of the antipsychotic drugs haloperidol and risperidone on behavioural effects induced by ketamine in mice, Sci Pharm, 76, 4, pp. 673-687, (2008)
  • [5] Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., Newton R.S., La Du B., Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants, Free Radic Biol Med, 26, 7-8, pp. 892-904, (1999)
  • [6] Beaudoin F.L., Lin C., Guan W., Merchant R.C., Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial, Acad Emerg Med, 21, 11, pp. 1193-1202, (2014)
  • [7] Becker A., Grecksch G., Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity, Prog Neuro-Psychopharmacol Biol Psychiatry, 28, pp. 1267-1277, (2004)
  • [8] Brinholi F.F., Noto C., Maes M., Bonifacio K.L., Brietzke E., Ota V.K., Gadelha A., Cordeiro Q., Belangero S.I., Bressan R.A., Vargas H.O., Higachi L., de Farias C.C., Moreira E.G., Barbosa D.S., Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug naïve first episode psychosis, Schizophr Res, 166, 1-3, pp. 225-230, (2015)
  • [9] Canever L., Oliveira L., D'Altoé de Luca R, Correa PT, de B Fraga D, Matos MP, Scaini G, Quevedo J, Streck EL, Zugno AI, A rodent model of schizophrenia reveals increase in creatine kinase activity with associated behavior changes. Oxidative Med Cell Longev, 3, 6, pp. 421-427, (2010)
  • [10] Cervellati C., Trentini A., Romani A., Bellini T., Bosi C., Ortolani B., Zurlo A., Passaro A., Seripa D., Zuliani G., Serum paraoxonase and arylesterase activities of paraoxonase-1 (PON-1), mild cognitive impairment, and 2-year conversion to dementia: a pilot study, J Neurochem, 135, 2, pp. 395-401, (2015)